Navigation Links
Purple corn compound may aid in developing future treatments for Type 2 diabetes, kidney disease
Date:9/18/2012

BETHESDA, Md. (Sept. 18, 2012)Diabetic nephropathy is one of the most serious complications related to diabetes, often leading to end-stage kidney disease. Purple corn grown in Peru and Chile is a relative of blue corn, which is readily available in the U.S. The maize is rich in anthocyanins (also known as flavonoids), which are reported to have anti-diabetic properties. Scientists from the Department of Food and Nutrition and Department of Biochemistry at Hallym University in Korea investigated the cellular and molecular activity of purple corn anthocyanins (PCA) to determine whether and how it affects the development of diabetic nephropathy (DN). Their findings suggest that PCA inhibits multiple pathways involved in the development of DN, which may help in developing therapies aimed at type 2 diabetes and kidney disease.

The study is entitled "Purple corn anthocyanins inhibit diabetes-associated glomerular monocyte activation and macrophage infiltration" http://bit.ly/SlrkRY. It appears in the online edition of the American Journal of Physiology Renal Physiology, published by the American Physiological Society (APS; www.the-aps.org).

Methodology

Researcher Min-Kyung Kang and colleagues performed a two-part study, an in vitro experiment investigating the effects of PCA on human endothelial cells cultured under hyperglycemic kidney conditions and an in vivo study that investigated the effects of PCA on kidney tissue in diabetic mice. In the in vitro experiment, cultured cells were exposed to 1-20 g/ml of PCA for six hours (control cells were not exposed), then assessed for level of monocyte-endothelial cell adhesion, a major factor in the development of diabetic glomerulosclerosis. In the in vivo experiment, diabetic and control mice were dosed with PCA for eight weeks, then changes in kidney tissue were assessed and immunohistological analyses were performed. Kidney tissue was further analyzed for levels of inflammatory chemokines, which are key components in DN.

Results

Researchers found that in human endothelial cells cultured in hyperglycemic kidney conditions, induction of endothelial cell adhesion molecules decreased in a dose-dependent manner with PCA exposure, meaning that the PCA likely interfered with cell-cell adhesion in glomeruli. PCA also appeared to interfere with leukocyte recruitment and adhesion to glomerular endothelial cells. In diabetic mice, PCA exposure slowed mesangial expansion and interrupted the cellular signaling pathway that may instigate glomerular adhesion and infiltration of inflammatory cells responsible for diabetic glomerulosclerosis. Finally, PCA inhibited levels of macrophage inflammatory protein-2 and monocyte chemotactic protein-1 in kidney tissue, demonstrating that it may inhibit macrophage infiltration, which is closely related to renal inflammation.

Importance of the Findings

The research suggests that anthocyanins may be the main biofunctional compound in purple corn and could protect against mesangial activation of monocytes and infiltration of macrophages in glomerulithe two major contributors to DN. The research further suggests that renoprotection by PCA against mesangial activation may be specific therapies targeting diabetes-associated diabetic glomerulosclerosis and renal inflammation. Finally, PCA supplementation may be an important strategy in preventing renal vascular disease in type 2 diabetes.

"PCA may be a potential renoprotective agent treating diabetes-associated glomerulosclerosis," wrote the researchers.


'/>"/>

Contact: Donna Krupa
dkrupa@the-aps.org
American Physiological Society
Source:Eurekalert

Related biology news :

1. Screening technique uncovers 5 new plant activator compounds
2. Mushroom-derived compound lengthens survival in dogs with cancer, Penn Vet study finds
3. Compound discovered that boosts effect of vaccines against HIV and flu
4. MMV develops framework to assess risk of resistance for antimalarial compounds
5. Compounds shown to thwart stubborn pathogens social propensity
6. University of Albertas designer compounds inhibit prion infection
7. Scripps Research scientists show potent new compound virtually eliminates HIV in cell culture
8. Poisoning from industrial compounds can cause similar effects to ALS
9. New compound holds promise for treating Duchenne MD, other inherited diseases
10. Nonstoichiometric Compounds V - An ECI Conference Series
11. New drug-screening method yields long-sought anti-HIV compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
(Date:12/16/2016)... , Dec 16, 2016 Research and ... System Market - Global Forecast to 2021" report to their ... The ... to grow at a CAGR of 14.06% from 2016 to 2021. ... and is projected to reach 854.8 Million by 2021. The growth ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
Breaking Biology News(10 mins):
(Date:1/11/2017)... ... January 11, 2017 , ... While the most acute effects ... becoming increasingly clear that the evolution and transmission dynamics of resistance gene dissemination ... study of clinical resistance, has vastly underestimated these reservoirs of resistance genes. ...
(Date:1/11/2017)... ... January 11, 2017 , ... For ... difference when navigating the challenges young businesses face. With the second installment of ... and experience of Geoff DiMasi, Founder and Principal of interactive design agency, P’unk ...
(Date:1/11/2017)... (PRWEB) , ... January 11, 2017 , ... ... business development professional has joined its team. Bernhard Bartylla will lead European initiatives ... working with Bernhard to introduce ACOMP and ARGEN to European manufacturers and researchers. ...
(Date:1/11/2017)... Md. , Jan. 11, 2017  GenVec, ... gene delivery company, announced today that its chief ... present a talk entitled  "AdenoVerse™ platform for translational ... the Biotech Showcase at the upcoming Phacilitate Cell ... Miami , Florida.  Dr. Brough,s presentation ...
Breaking Biology Technology: